Cancer immunotherapy has transformed oncology by shifting part of the fight against tumors from conventional chemotherapy and radiation toward the patient’s own immune system. Among the most important advances are immune checkpoint inhibitors, which release molecular brakes that restrain T cells, and engineered or expanded T-cell therapies designed to target malignant cells. Yet these treatments remain ineffective for many patients. Some tumors lack the biological signals needed for T-cell recognition, while others create a hostile microenvironment that suppresses immune activity or evolve rapidly enough to escape attack.

T cells are specialized immune cells capable of identifying abnormal proteins displayed on the surface of cancer cells. After recognizing their targets, they form a close contact zone with the tumor cell, known as an immunological synapse, and release toxic molecules that can trigger the cancer cell to die. This process depends on a series of precisely coordinated interactions between the T cell and the tumor. If any part of that process is weakened—whether because the tumor hides its identifying markers, blocks immune signaling or resists cell death—the immune response may fail even when large numbers of T cells are present.

To search for ways to overcome these barriers, Puig-Saus’ laboratory has developed a drug screening platform capable of testing thousands of chemical compounds. Such platforms allow scientists to observe how individual molecules influence interactions between immune cells and cancer cells. Rather than examining only whether a drug kills tumor cells directly, the UCLA team can investigate whether a compound changes the biological relationship between the tumor and the immune system. This distinction is important because many promising immunotherapy-enhancing drugs may not be effective as standalone cancer treatments.

The screening effort has identified two leading candidates with complementary effects. One compound appears to strengthen the physical and functional interaction between T cells and cancer cells. By improving the formation or stability of the cellular contact needed for immune attack, the drug could help T cells deliver their destructive signals more effectively. This type of intervention may be especially valuable in tumors where immune cells reach the cancer but fail to establish a sufficiently strong or sustained response.

The second candidate acts primarily on tumor cells rather than directly modifying T cells. Preliminary findings suggest that it makes cancer cells more vulnerable to destruction by T cells. In technical terms, the drug may alter pathways controlling tumor-cell survival, stress responses or susceptibility to the molecular machinery released by activated immune cells. The compound could therefore increase the “killability” of cancer cells without requiring researchers to permanently reprogram or intensify the immune cells themselves, potentially offering a different route to improving treatment efficacy.

The new grant will support experiments in preclinical melanoma models to determine whether either compound can boost existing immunotherapies. Researchers will evaluate combinations with immune checkpoint inhibitors and T-cell-based treatments, measuring tumor growth, immune-cell activity, treatment durability and possible toxic effects. They will also study how the compounds work at the molecular level, seeking to identify the cellular pathways responsible for improved immune recognition or tumor destruction. Understanding those mechanisms will be essential for selecting appropriate patients and designing safe clinical trials.

Melanoma provides a particularly important testing ground because it can carry a high number of mutations, creating abnormal proteins that immune cells may recognize. Despite this vulnerability, melanoma can still suppress immune responses and develop resistance after an initial treatment benefit. A drug that restores the effectiveness of T cells or exposes a tumor’s hidden weaknesses could help extend responses in patients who do not benefit from current therapies or whose cancers return after treatment. The researchers will need to establish whether the compounds work broadly across genetically different melanomas or only in tumors with particular biological features.

“If successful, these drugs could significantly improve the effectiveness of current immunotherapies and help more patients benefit from these treatments,” Puig-Saus said. She is an associate professor of microbiology, immunology and molecular genetics and surgical oncology at the David Geffen School of Medicine at UCLA. She is also a member of the UCLA Broad Stem Cell Research Center and the UCLA Parker Institute for Cancer Immunotherapy. Because the compounds are being developed as partners for existing treatments rather than replacements for them, the strategy could potentially be adapted to other cancers in which immune evasion and resistance limit therapeutic success.

The project remains at the preclinical stage, and its compounds have not yet been established as safe or effective treatments for people. Many candidates that show promise in laboratory systems ultimately fail because they produce unexpected toxicity, lose activity in complex tumors or cannot be delivered at useful doses. The UCLA team’s upcoming studies will therefore examine both therapeutic benefit and safety while tracing the precise mechanisms involved. If the candidates continue to perform well, they could provide a foundation for future clinical development and offer a new way to make the immune system’s attack on cancer more precise, persistent and effective.

Subject of Research: Cancer immunotherapy enhancement using drug-based strategies for melanoma and potentially other cancers

Article Title: UCLA Team Receives $3.9 Million Grant to Develop Drugs That Could Strengthen Cancer Immunotherapy

Web References: https://www.uclahealth.org/cancer/members/cristina-puig-saus; https://www.uclahealth.org/cancer

Keywords: Immunotherapy, cancer immunology, immune system, immune response, cancer research, cancer, melanoma, skin cancer, T-cell therapy, immune checkpoint inhibitors

Traditional cancer therapies often rely on broad mechanisms such as chemotherapy or checkpoint inhibition, which can lead to severe side effects and variable patient responses. Against this backdrop, targeted protein degradation has emerged as a promising strategy, harnessing the cell’s natural machinery to selectively eliminate disease-causing proteins. Molecular glues are small molecules that facilitate novel interactions between a target protein and an E3 ubiquitin ligase, marking the target for destruction. However, designing molecular glues with high specificity has been notoriously challenging due to the complex and intertwined structural landscapes involved.

PVTX-405 distinguishes itself by selectively binding to IKZF2, a transcription factor that plays a pivotal role in immune regulation and cancer cell survival. IKZF2, also known as Helios, is part of the Ikaros family of zinc finger proteins involved in lymphocyte development and function. Aberrant regulation of IKZF2 has been implicated in the immune evasion mechanisms of various tumors, making it an attractive, yet difficult, therapeutic target. The molecular glue mechanism employed by PVTX-405 recruits IKZF2 to a specific E3 ubiquitin ligase complex, triggering its degradation, thereby dismantling malignant cells’ evasion capabilities and potentiating immune system activity against the cancer.

The study details a comprehensive suite of biochemical, structural, and cellular assays that elucidate the mechanism of PVTX-405’s interaction with IKZF2 and the E3 ligase. The researchers used high-resolution cryo-electron microscopy and X-ray crystallography to map the binding interface, revealing how PVTX-405 induces a stable ternary complex between IKZF2 and the E3 ligase. This intricate molecular choreography results in ubiquitination of IKZF2 and subsequent proteasomal degradation. Crucially, the compound does not promote the degradation of closely related Ikaros family members, highlighting its exceptional selectivity—a major milestone for molecular glue technology.

One of the most compelling features of PVTX-405 is its ability to circumvent the common problem of acquired resistance seen with other targeted therapies. By inducing degradation rather than merely inhibiting function, the compound reduces the likelihood of compensatory mechanisms that allow cancer cells to persist. Furthermore, the selective nature of PVTX-405 minimizes off-target effects, potentially reducing the adverse immune-related toxicities seen with conventional immunotherapies.

In cell-based models, treatment with PVTX-405 resulted in robust degradation of IKZF2, leading to a marked reduction in tumor cell proliferation. Immune effector assays demonstrated enhanced anti-tumor cytotoxicity in the presence of PVTX-405, suggesting that degradation of IKZF2 reprograms the tumor microenvironment to favor immune-mediated clearance. These outcomes were corroborated in murine models of several hematologic malignancies, where the compound showed potent anti-cancer effects without inducing significant systemic toxicity.

The therapeutic implications of PVTX-405 extend beyond hematologic cancers. IKZF2 has been associated with regulatory T-cell function, which contributes to immunosuppressive networks within solid tumors. By selectively degrading IKZF2, PVTX-405 has the potential to modulate these immunosuppressive circuits, opening avenues for combinatory regimens with checkpoint inhibitors or adoptive cell therapies in refractory solid tumors. The strategic targeting of transcription factors, traditionally considered “undruggable,” through molecular glue mediators like PVTX-405, heralds a new chapter in overcoming tumor immune escape.

Another critical aspect of the research was the meticulous optimization of PVTX-405’s pharmacokinetic and pharmacodynamic properties. Structure-activity relationship analyses facilitated the refinement of the molecule for improved bioavailability, metabolic stability, and tissue distribution—all essential parameters for clinical translation. The compound’s oral bioavailability and favorable half-life position it as a practical candidate for long-term treatment regimens, enhancing patient compliance and therapeutic impact.

Despite the exciting preclinical data, several hurdles remain before PVTX-405 can be fully integrated into clinical practice. The authors highlight the need for comprehensive toxicology studies to assess potential immune-related side effects in humans. Moreover, understanding the long-term consequences of sustained IKZF2 depletion on normal immune homeostasis is essential to mitigate risks of autoimmunity or immunodeficiency. Nonetheless, the precise targeting mechanism underlying PVTX-405 provides a strong foundation for rational design of next-generation molecular glues with improved safety profiles.

This study also underscores the vital role of interdisciplinary collaboration in drug discovery. Integrating computational modeling, chemical biology, structural biochemistry, and immunology enabled a holistic approach to optimizing PVTX-405’s efficacy and selectivity. The iterative feedback between experimental data and molecular design exemplifies how modern biomedical research can rapidly accelerate the translation of novel compounds from bench to bedside.

PVTX-405’s discovery reiterates the transformative potential of targeted protein degradation as a therapeutic paradigm. Unlike classical inhibitors that rely on occupancy and reversible binding, molecular glue degraders exploit the cell’s quality control machinery to achieve sustained protein knockdown. This paradigm shift may allow clinicians to overcome resistance mutations that impair target binding, a persistent challenge in precision oncology.

A particularly fascinating aspect of this work is the elucidation of the molecular glue’s capacity to induce novel protein-protein interactions. By bridging IKZF2 and an E3 ligase that do not normally interact, PVTX-405 exemplifies the power of small molecules to expand the “interactome” landscape within cells. This concept not only enhances druggable targets but also promotes discovery of cryptic regulatory pathways amenable to chemical intervention.

PVTX-405’s ability to toggle immune effector functions through targeted degradation suggests exciting applications beyond oncology. Autoimmune diseases, chronic infections, and other immune dysregulation disorders could benefit from similarly engineered molecular glues that rewire immune signaling networks in a controlled and reversible manner. The modular nature of molecular glues opens considerable scope for broadening this therapeutic class across diverse disease spectra.

From a commercial and clinical perspective, PVTX-405 represents a compelling asset with significant market potential. The demand for efficacious and tolerable cancer immunotherapies continues to grow, invigorated by advances in immuno-oncology. If successful in clinical trials, PVTX-405 could fill a critical niche where current therapies fail or induce harmful immune-related adverse events, ultimately improving patient survival and quality of life.

In summary, the development of PVTX-405 as a potent, selective molecular glue degrader of IKZF2 is a landmark achievement in cancer immunotherapy research. It exemplifies the convergence of cutting-edge science and therapeutic innovation, offering a novel weapon in the arsenal against cancer. As the research community continues to unravel molecular glue mechanisms and expand their application, PVTX-405 stands as a beacon of hope for more effective, targeted, and less toxic treatments in oncology and beyond.

Subject of Research: Development of a selective molecular glue degrader targeting IKZF2 for cancer immunotherapy.

Article Title: Development of PVTX-405 as a potent and highly selective molecular glue degrader of IKZF2 for cancer immunotherapy.

Article References:
Chen, Z., Dhruv, H., Zhang, X. et al. Development of PVTX-405 as a potent and highly selective molecular glue degrader of IKZF2 for cancer immunotherapy. Nat Commun 16, 4095 (2025). https://doi.org/10.1038/s41467-025-58431-z

Image Credits: AI Generated